Rivoglitazone - Misplaced Pages

Chemical compound Pharmaceutical compound

Rivoglitazone
Clinical data

ATC code	none
Identifiers
IUPAC name (RS)-5-{4-benzyl}-1,3-thiazolidine-2,4-dione
CAS Number	185428-18-6
PubChem CID	3055168
ChemSpider	2316729
UNII	3A3N0634Q6
ChEMBL	ChEMBL2104753
CompTox Dashboard (EPA)	DTXSID00870164
Chemical and physical data
Formula	C₂₀H₁₉N₃O₄S
Molar mass	397.45 g·mol
3D model (JSmol)	Interactive image
SMILES CN1C2=C(C=CC(=C2)OC)N=C1COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4
InChI InChI=1S/C20H19N3O4S/c1-23-16-10-14(26-2)7-8-15(16)21-18(23)11-27-13-5-3-12(4-6-13)9-17-19(24)22-20(25)28-17/h3-8,10,17H,9,11H2,1-2H3,(H,22,24,25) Key:XMSXOLDPMGMWTH-UHFFFAOYSA-N
(verify)

Rivoglitazone (INN) is a thiazolidinedione derivative undergoing research for use in the treatment of type 2 diabetes.

It is being developed by Daiichi Sankyo.

References

Schimke K, Davis TM (April 2007). "Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes". Current Opinion in Investigational Drugs. 8 (4): 338–344. PMID 17458185.
Kong AP, Yamasaki A, Ozaki R, Saito H, Asami T, Ohwada S, et al. (September 2011). "A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes". Diabetes, Obesity & Metabolism. 13 (9): 806–813. doi:10.1111/j.1463-1326.2011.01411.x. PMID 21492364. S2CID 24974160.

Oral diabetes medication, insulins and insulin analogs, and other drugs used in diabetes (A10)

Insulins / insulin analogs

fast-acting	Insulin aspart Insulin glulisine Insulin lispro
short-acting	Regular insulin
long-acting	Insulin detemir Insulin glargine (+lixisenatide) NPH insulin Lente insulin Ultralente insulin
ultra-long-acting	Insulin degludec (+insulin aspart, +liraglutide) Insulin icodec (+semaglutide)
inhalable	Exubera Afrezza

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

Non-insulins

Insulin sensitizers

Biguanides	Buformin Metformin Phenformin
TZDs/"glitazones" (PPAR)	Ciglitazone Darglitazone Englitazone Lobeglitazone Netoglitazone Pioglitazone Rivoglitazone Rosiglitazone Troglitazone
Dual PPAR agonists	Aleglitazar Muraglitazar Saroglitazar Tesaglitazar
Amylin analogs and DACRAs	Cagrilintide Pramlintide

Secretagogues

K_ATP

Sulfonylureas

2nd generation: Glibenclamide (glyburide)
Glibornuride
Glicaramide
Gliclazide
Glimepiride
Glipizide
Gliquidone
Glisoxepide
Glyclopyramide

Meglitinides/"glinides"

GLP-1 receptor agonists

GLP1 poly-agonist peptides	Mazdutide (GLP-1/GCGR) Retatrutide (GLP-1/GIP/GCGR) Tirzepatide (GLP-1/GIP)

DPP-4 inhibitors/"gliptins"

Other

Aldose reductase inhibitors	Epalrestat Fidarestat Ranirestat Tolrestat Zenarestat
Alpha-glucosidase inhibitors	Acarbose Miglitol Voglibose
SGLT2 inhibitors/"gliflozins"	Canagliflozin Dapagliflozin Empagliflozin Ertugliflozin Ipragliflozin Luseogliflozin Remogliflozin Sergliflozin Sotagliflozin Tofogliflozin Velagliflozin
Other	Benfluorex Bromocriptine Imeglimin

Combinations

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

v t e PPARTooltip Peroxisome proliferator-activated receptor modulators
PPARαTooltip Peroxisome proliferator-activated receptor alpha	Agonists: 15-HETE 15-HpETE Aleglitazar Aluminium clofibrate Arachidonic acid Bezafibrate Chiglitazar Clofibrate CP-775146 Daidzein DHEA (prasterone) (in rodents) Elafibranor Etomoxir Fenofibrate Genistein Gemfibrozil GW-7647 Lanifibranor Leukotriene B₄ LG-101506 LG-100754 Lobeglitazone Muraglitazar Oleylethanolamide Palmitoylethanolamide Pemafibrate Perfluorononanoic acid Perfluorooctanoic acid Pioglitazone Saroglitazar Sodelglitazar Tesaglitazar Tetradecylthioacetic acid Troglitazone WY-14643 Antagonists: GW-6471 MK-886
PPARδTooltip Peroxisome proliferator-activated receptor delta	Agonists: 15-HETE 15-HpETE Arachidonic acid Bezafibrate Daidzein Elafibranor Fonadelpar Genistein GW-0742 GW-501516 L-165,041 Lanifibranor LG-101506 Seladelpar Sodelglitazar Tetradecylthioacetic acid Antagonists: FH-535 GSK-0660 GSK-3787
PPARγTooltip Peroxisome proliferator-activated receptor gamma	Agonists: 5-Oxo-ETE 5-Oxo-15-hydroxy-ETE 15-Deoxy-Δ-prostaglandin J₂ 15-HETE 15-HpETE Aleglitazar Arachidonic acid Balaglitazone Berberine Bezafibrate Cannabidiol Cevoglitazar Chiglitazar Ciglitazone Daidzein Darglitazone Edaglitazone Efatutazone Englitazone Etalocib Farglitazar Genistein GW-1929 Ibuprofen Imiglitazar Indeglitazar Lanifibranor LG-100268 LG-100754 LG-101506 Lobeglitazone Muraglitazar (muroglitazar) nTZDpa Naveglitazar Netoglitazone Oxeglitazar Peliglitazar Pemaglitazar Perfluorononanoic acid Pioglitazone Prostaglandin J₂ Ragaglitazar Reglitazar Rivoglitazone Rosiglitazone RS5444 Saroglitazar Sipoglitazar Sodelglitazar Telmisartan Tesaglitazar Troglitazone SPPARMsTooltip Selective PPARγ modulator: BADGE EPI-001 INT-131 MK-0533 S26948 Antagonists: FH-535 GW-9662 SR-202 T-0070907 Unknown: SR-1664
Non-selective	Agonists: Ciprofibrate Clinofibrate Clofibride Englitazone Etofibrate Farglitazar Netoglitazone Ronifibrate Rivoglitazone Simfibrate
See also Receptor/signaling modulators

This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it.

Categories: